These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 35222540)
1. Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis. Zhao Y; Wu J; Li L; Zhang H; Zhang H; Li J; Zhong H; Lei T; Jin Y; Xu B; Song Q Front Genet; 2022; 13():820135. PubMed ID: 35222540 [No Abstract] [Full Text] [Related]
2. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2. Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y Front Immunol; 2023; 14():1155182. PubMed ID: 37275857 [TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
4. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy. Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253 [TBL] [Abstract][Full Text] [Related]
5. A comprehensive pan-cancer analysis identifies a novel glycolysis score and its hub genes as prognostic and immunological biomarkers. Zheng D; Long S; Xi M Transl Cancer Res; 2023 Oct; 12(10):2852-2874. PubMed ID: 37969385 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer. Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507 [TBL] [Abstract][Full Text] [Related]
7. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis. Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111 [No Abstract] [Full Text] [Related]
8. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer. Xu Q; Chen S; Hu Y; Huang W Front Immunol; 2021; 12():711433. PubMed ID: 34512634 [TBL] [Abstract][Full Text] [Related]
9. Potential immunologic and prognostic roles of CHRNA6 in SCLC and pan-cancer. Zhao Q; Wang C; Huang W; Song Z; Lang Y; Zhu X Heliyon; 2024 Oct; 10(19):e38572. PubMed ID: 39398083 [TBL] [Abstract][Full Text] [Related]
10. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model. Zheng K; Hai Y; Chen H; Zhang Y; Hu X; Ni K J Transl Med; 2024 Apr; 22(1):365. PubMed ID: 38632658 [TBL] [Abstract][Full Text] [Related]
11. IFN-α/β/IFN-γ/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype. Wang L; Wei Y; Jin Z; Liu F; Li X; Zhang X; Bai X; Jia Q; Zhu B; Chu Q Clin Exp Med; 2024 May; 24(1):102. PubMed ID: 38758367 [TBL] [Abstract][Full Text] [Related]
12. The Prognostic and Immunological Value of Guanylate-Binding Proteins in Lower-Grade Glioma: Potential Markers or Not? Liu Z; Sun J; Gong T; Tang H; Shen Y; Liu C Front Genet; 2021; 12():651348. PubMed ID: 34759950 [TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy. Tu Z; Li K; Ji Q; Huang Y; Lv S; Li J; Wu L; Huang K; Zhu X BMC Cancer; 2023 Feb; 23(1):133. PubMed ID: 36759763 [TBL] [Abstract][Full Text] [Related]
14. Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer. Guo JN; Chen D; Deng SH; Huang JR; Song JX; Li XY; Cui BB; Liu YL Cancer Immunol Immunother; 2022 Jun; 71(6):1313-1330. PubMed ID: 34657172 [TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor. Mo Z; Li P; Cao Z; Zhang S Front Immunol; 2021; 12():564948. PubMed ID: 34290693 [TBL] [Abstract][Full Text] [Related]
17. Correlation of PADI4, GBP1, miR-215, and TMB Expression Levels with Clinical Characteristics and Prognosis of Lung Cancer. Chen J; Han Y; Zhao Y; Zhu W Altern Ther Health Med; 2023 Jul; 29(5):238-241. PubMed ID: 37052970 [TBL] [Abstract][Full Text] [Related]
18. Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort. Li C; Ding Y; Zhang X; Hua K Discov Oncol; 2022 Jul; 13(1):65. PubMed ID: 35834061 [TBL] [Abstract][Full Text] [Related]
19. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy. Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107 [TBL] [Abstract][Full Text] [Related]
20. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients. Wang G; Miao C; Mo L; Kahlert UD; Wu J; Ou M; Huang R; Feng R; Pang W; Shi W Front Immunol; 2022; 13():1048503. PubMed ID: 36582246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]